Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Receives Average Recommendation of “Buy” from Brokerages

Shares of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) have been given a consensus rating of “Buy” by the ten research firms that are currently covering the company, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $8.95.

Several research firms have recently commented on INFI. B. Riley lowered their price objective on shares of Infinity Pharmaceuticals from $7.00 to $4.00 and set a “buy” rating for the company in a research note on Wednesday, July 28th. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Infinity Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.50 target price for the company in a research report on Wednesday, October 6th. JPMorgan Chase & Co. upgraded shares of Infinity Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $6.00 target price for the company in a research report on Monday, August 2nd. Wells Fargo & Company upgraded shares of Infinity Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $4.00 to $14.00 in a research report on Wednesday, July 28th. Finally, HC Wainwright assumed coverage on shares of Infinity Pharmaceuticals in a research report on Monday, October 18th. They set a “buy” rating and a $9.00 target price for the company.

NASDAQ INFI traded up $0.05 on Friday, hitting $2.27. The stock had a trading volume of 511,957 shares, compared to its average volume of 3,849,047. The business’s fifty day moving average price is $2.82 and its 200 day moving average price is $2.98. Infinity Pharmaceuticals has a 52-week low of $1.48 and a 52-week high of $5.98. The stock has a market cap of $202.06 million, a price-to-earnings ratio of -3.98 and a beta of 1.91.

Infinity Pharmaceuticals (NASDAQ:INFI) last released its quarterly earnings results on Tuesday, November 2nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.02. Infinity Pharmaceuticals had a negative net margin of 2,398.81% and a negative return on equity of 172.12%. The business had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.45 million. During the same period in the previous year, the company earned ($0.16) earnings per share. On average, analysts predict that Infinity Pharmaceuticals will post -0.53 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC purchased a new stake in shares of Infinity Pharmaceuticals during the first quarter worth about $737,000. Dimensional Fund Advisors LP purchased a new stake in shares of Infinity Pharmaceuticals during the second quarter worth about $307,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Infinity Pharmaceuticals during the second quarter worth about $161,000. JPMorgan Chase & Co. increased its stake in shares of Infinity Pharmaceuticals by 59,910.7% during the second quarter. JPMorgan Chase & Co. now owns 33,606 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 33,550 shares in the last quarter. Finally, Virtu Financial LLC increased its stake in shares of Infinity Pharmaceuticals by 83.1% during the second quarter. Virtu Financial LLC now owns 115,312 shares of the biotechnology company’s stock worth $345,000 after purchasing an additional 52,328 shares in the last quarter. 55.14% of the stock is owned by institutional investors and hedge funds.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.

Featured Article: How can investors benefit from after-hours trading?

Analyst Recommendations for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.